Online citations, reference lists, and bibliographies.
← Back to Search

Additive Effect Of Elcatonin To Risedronate For Chronic Back Pain And Quality Of Life In Postmenopausal Women With Osteoporosis: A Randomized Controlled Trial

M. Hongo, N. Miyakoshi, Y. Kasukawa, Y. Ishikawa, Y. Shimada
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Calcitonin has been reported to reduce acute and chronic back pain in osteoporotic patients. The additive effect of calcitonin with a bisphosphonate on chronic back pain remains unclear. The purpose of this study was to evaluate the effect of combining elcatonin (eel calcitonin) with risedronate for patients with chronic back pain. Forty-five postmenopausal women diagnosed as having osteoporosis with chronic back pain persisting for more than 3 months, after excluding women with fresh vertebral fractures within the last 6 months, were randomly allocated to a risedronate group (risedronate alone, n = 22) and a combined group (risedronate and elcatonin, n = 23). The study period was 6 months. Pain was evaluated with a visual analogue scale (VAS) and the Roland-Morris questionnaire (RDQ). Back extensor strength, bone mineral density, and quality of life on the SF-36 and the Japanese osteoporosis quality of life score were also evaluated. Significant improvements were found in the combined group for VAS at final follow-up compared with baseline and 3 months, mental health status on the SF-36, and JOQOL domains for back pain and general health. The JOQOL domain for back pain improved significantly, but no change was found in the VAS or other domains in the risedronate group. Bone mineral density increased significantly in the two groups, but no significant difference was found between the groups. Back extensor strength did not change in both groups. In conclusion, the use of elcatonin in addition to risedronate for more than 3 months reduced chronic back pain. The additional therapy of risedronate with elcatonin may be a useful and practical choice for the treatment of osteoporosis with chronic back pain persisting more than 3 months.
This paper references
Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study
N. V. Schoor (2004)
Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36
Takuo Fujita (2011)
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures
S. Ohtori (2010)
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis
S. Itoh (2012)
The effect of calcitonin on β-endorphin levels in postmenopausal osteoporotic patients with back pain
D. Ofluoğlu (2006)
[Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis].
M. Abellán Pérez (1995)
Analgesic mechanism of calcitonin
M. Yoshimura (2000)
Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis
N. Miyakoshi (2003)
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
P. Hadji (2011)
Intranasal Salcatonin (Salmon Calcitonin) A Review of its Pharmacological Properties and Role in the Management of Postmenopausal Osteoporosis
D. Agnusdei (1996)
Mechanisms for Ovariectomy-Induced Hyperalgesia and Its Relief by Calcitonin: Participation of 5-HT1A-Like Receptor on C-Afferent Terminals in Substantia Gelatinosa of the Rat Spinal Cord
Akitoshi Ito (2000)
Diagnostic criteria for primary osteoporosis: year 2012 revision
S. Soen (2013)
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
J. Ringe (2006)
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study
T. Nakamura (2012)
Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
G. Mazzuoli (2007)
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
G. Wells (2008)
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
D. Wysowski (2005)
Superi - ority of a combined treatment of Alendronate and Alfacalcidol 438
Y Dionyssiotis (2007)
Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.
G. Lyritis (1997)
Analgesic effect of Salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study
G. Lyritis (2007)
A useful technique for measurement of back strength in osteoporotic and elderly patients.
P. Limburg (1991)
The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis
G. Papadokostakis (2005)
A clinical trial on the effects of a combination of elcatonin (Carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women
M. Meschia (2005)
Diagnostic criteria for primary osteoporosis: year 2000 revision
H. Orimo (2001)
A population based study
P. McIntyre (1993)
Validation of the Japanese Osteoporosis Quality of Life Questionnaire
K. Kumamoto (2009)
Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study.
G. Lyritis (1999)
Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: A double-blind, double-placebo study
A. Pontiroli (1994)
Calcitonin for Treating Acute and Chronic Pain of Recent and Remote Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta Analysis
Jennifer A. Knopp-Sihota (2010)
Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Masayuki Takakuwa (2012)
A useful technique for measurement of back strength in osteoporotic and elderly patients
P. Limburg (1991)
Prevalence of Back Pain in Postmenopausal Osteoporosis and Associations with Multiple Spinal Factors
Naohisa Miyakoshi (2012)
Calcitonin induced increase in ACTH, beta-endorphin and cortisol secretion.
L. Laurian (1986)
Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.
Y. Ishida (2004)
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
D. Wysowski (2005)
Reduced risk of back pain following teriparatide treatment: a meta-analysis
M. Nevitt (2005)
The Analgesic Role of Calcitonin Following Osteoporotic Fracture
S. Silverman (2002)
Calcitonin inhibits basal and thyrotropin-releasing hormone-induced release of prolactin from anterior pituitary cells: evidence for a selective action exerted proximal to secretagogue-induced increases in cytosolic Ca2+.
G. V. Shah (1990)
Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin
R. Franceschini (2004)
Calcitonin induced increase in ACTH, β-endorphin and cortisol secretion
L. Laurian (1986)
Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials
J. Knopp (2004)

This paper is referenced by
Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials
W. Chen (2019)
Effect of elcatonin versus nonsteroidal anti-inflammatory medications for acute back pain in patients with osteoporotic vertebral fracture: a multiclinic randomized controlled trial
Naoto Endo (2016)
Efficacy and Safety of Bisphosphonates for Postmenopausal Women: A Systematic Review and Network Meta-analysis
Carine Zheng (2019)
The kinetic study of the thermally induced degradation and an evaluation of the drug–excipient interactions performed for a new-generation bisphosphonate—risedronate
Gabriela Vlase (2018)
Pathomechanisms and management of osteoporotic pain with no traumatic evidence
S. Orita (2017)
Strontium Ranelate and Calcitonin
Leonardo dos Santos Bandeira (2018)
Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis
L. Bandeira (2016)
Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures
S. Tanaka (2016)
Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate
M. Al-Bogami (2015)
Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
S. Tanaka (2017)
Interdisciplinary trust and respect protects patients from changing power dynamics in healthcare
Sahithi Gogineni (2019)
Effect of Thunder-Fire Moxibustion on Pain, Quality of Life, and Tension of Multifidus in Patients with Primary Osteoporosis: A Randomized Controlled Trial
D. Xu (2018)
Elcatonin attenuates disuse osteoporosis after fracture fixation of tubular bone in rats
Z. Ji (2015)
Semantic Scholar Logo Some data provided by SemanticScholar